Overexpression of NDRG2 promotes the therapeutic effect of pazopanib on ovarian cancer
Related Experiment Video
Updated: Dec 6, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Ying Cui1, Guihua Shen1, Linlin Ma1
1Department of Gynecology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P. R. China.
Objectives:
Ovarian cancer is the second commonly seen cancer in the US, patients with ovarian cancer are commonly diagnosed in the advanced stage. Pazopanib is an inhibitor of multiple tyrosine kinases and has been approved in treatment for carcinoma by FDA. N-myc downstream-regulated gene 2 (NDRG2) has been regarded as a cancer suppressor gene and presented an inhibition effect in cancer proliferation, invasion, and migration.
Abstract:
Design: NDRG2 was overexpressed or inhibited in SKOV-3 cells, then experiments were performed to detect the apoptosis of cells. The expression or secretion of pro-cancer molecules was detected. And the expression of apoptosis-related proteins and the ASK1/JNK1 signaling pathway was detected.
Methods:
The NDRG2 overexpression and inhibition model was firstly constructed in SKOV-3 cells, the apoptotic cells were detected using flow cytometry. The expression of cellular metastasis genes was detected using the qPCR method. The angiogenesis factors was detected using the ELISA method. Expression of each target protein was detected using western blotting analysis.
Results:
NDRG2 overexpression and inhibition model were constructed in the SKOV-3 cell line, overexpression of NDRG2 enhanced the effect of pazopanib on inhibition of the expression of metastasis-related molecules and angiogenesis-related factors. The apoptosis process of cells was also enhanced after overexpression of NDRG2, and these effects were regulated by the activation of the ASK1/JNK1 signaling pathway.
Abstract:
Limitations: The effect of NDRG2 in animal models and more cell lines needs to be explored in further study.
Conclusions:
NDRG2 might be a therapeutic target in treatment for ovarian cancer.
Insights
N-myc downstream-regulated gene 2 (NDRG2) overexpression enhances pazopanib
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ovarian cancer is frequently diagnosed at advanced stages in the US.
- Pazopanib, an FDA-approved tyrosine kinase inhibitor, is used in cancer treatment.
- N-myc downstream-regulated gene 2 (NDRG2) acts as a tumor suppressor, inhibiting cancer cell proliferation, invasion, and migration.
Purpose of the Study:
- To investigate the role of NDRG2 in ovarian cancer progression.
- To determine if NDRG2 can enhance the efficacy of pazopanib.
- To explore the underlying molecular mechanisms involving the ASK1/JNK1 signaling pathway.
Main Methods:
- NDRG2 was overexpressed or inhibited in the SKOV-3 ovarian cancer cell line.
- Apoptosis was assessed via flow cytometry.
- Metastasis and angiogenesis factors were quantified using qPCR and ELISA, respectively.
- Protein expression, including apoptosis-related proteins and the ASK1/JNK1 pathway, was analyzed by western blotting.
Main Results:
- Overexpression of NDRG2 potentiated pazopanib's inhibitory effects on metastasis and angiogenesis in SKOV-3 cells.
- NDRG2 overexpression significantly enhanced cancer cell apoptosis.
- These effects were mediated by the activation of the ASK1/JNK1 signaling pathway.
Conclusions:
- NDRG2 plays a crucial role in suppressing ovarian cancer progression.
- NDRG2 may serve as a valuable therapeutic target for ovarian cancer treatment.
- The ASK1/JNK1 pathway is implicated in NDRG2-mediated anti-cancer effects.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Treatment Resistant Cancers

